


Application Ser. No.: 09/937,045
 Filing Date: September 20, 2001
 Examiner: Thierry Gallet

Amendment Pursuant to 37 C.F.R. § 1.121

IN THE CLAIMS:

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. (currently amended) A compound corresponding to the formula (I)



in which

X represents an oxygen atom or a group of formula NZ in which Z represents a hydrogen atom or a (C₁-C₆)alkyl group,

n represents a number 0, 1 or 2, and

R₁, R₂, R₃, R₄ and R₅ each represent, independently of each other, a hydrogen or halogen atom or a trifluoromethyl, trifluoromethoxy, cyano, hydroxyl,

(C₁-C₆)alkyl, (C₁-C₆)alkoxy, phenoxy or phenyl group optionally substituted with a halogen atom or a trifluoromethyl, cyano, hydroxyl, (C₁-C₆)alkyl or

(C₁-C₆)alkoxy group, or alternatively R₂ and R₃ together form a group of formula -OCH₂O- or -CH₂CH₂CH₂CH₂-, or alternatively R₂ represents nitro, in the form of a base or of an addition salt with an acid,

2. (canceled)

3. (previously presented) A pharmaceutical composition comprising a compound according to Claim 1, combined with an excipient.

Application Ser. No.: 09/937,045
Filing Date: September 20, 2001
Examiner: Thierry Gallet

4. (canceled)

5. (previously presented) A method for the treatment of Alzheimer's disease or schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.

6. (canceled)

7. (previously presented) 4-Bromophenyl-1,4-diazabicyclo[3.2.2]nonane-4-carboxylate according to claim 1.

8. (previously presented) A pharmaceutical composition comprising a compound according to claim 7, combined with an excipient.

9. (previously presented) A method for the treatment of Alzheimer's disease or schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 7.

10. (canceled)